W Galbraith

1.0k total citations
24 papers, 833 citations indexed

About

W Galbraith is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, W Galbraith has authored 24 papers receiving a total of 833 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pharmacology and 4 papers in Organic Chemistry. Recurrent topics in W Galbraith's work include Inflammatory mediators and NSAID effects (5 papers), Osteoarthritis Treatment and Mechanisms (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). W Galbraith is often cited by papers focused on Inflammatory mediators and NSAID effects (5 papers), Osteoarthritis Treatment and Mechanisms (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). W Galbraith collaborates with scholars based in United States and United Kingdom. W Galbraith's co-authors include Irwin Goldstein, Elizabeth C. Arner, Ido Goldstein, Gary L. Davis, Bernadette Lyons-Giordano, Janet S. Kerr, Neil R. Ackerman, Michael A. Pratta, W. Schmidt and Richard J. Roman and has published in prestigious journals such as Biochemistry, Biochemical and Biophysical Research Communications and FEBS Letters.

In The Last Decade

W Galbraith

24 papers receiving 785 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W Galbraith United States 14 277 272 255 124 116 24 833
Takeki Okumoto Japan 15 726 2.6× 217 0.8× 299 1.2× 147 1.2× 39 0.3× 38 1.2k
Shu Xu United States 19 334 1.2× 347 1.3× 323 1.3× 85 0.7× 55 0.5× 36 1.0k
Shaukat H. Rangwala United States 11 566 2.0× 553 2.0× 204 0.8× 89 0.7× 369 3.2× 17 1.3k
Sherrill Nurnberg United States 5 229 0.8× 286 1.1× 162 0.6× 131 1.1× 114 1.0× 7 661
Daniel Poeckel Germany 18 717 2.6× 473 1.7× 119 0.5× 165 1.3× 78 0.7× 23 1.3k
R. R. Martel United States 14 361 1.3× 245 0.9× 260 1.0× 89 0.7× 25 0.2× 27 857
Jens Breinholt Denmark 17 350 1.3× 266 1.0× 330 1.3× 51 0.4× 37 0.3× 40 1.1k
Tetsuo Ohnuki Japan 16 639 2.3× 208 0.8× 395 1.5× 52 0.4× 44 0.4× 32 1.1k
J L Currie United States 7 132 0.5× 117 0.4× 145 0.6× 105 0.8× 35 0.3× 10 529
Hyeun‐Wook Chang South Korea 23 665 2.4× 254 0.9× 88 0.3× 234 1.9× 66 0.6× 50 1.2k

Countries citing papers authored by W Galbraith

Since Specialization
Citations

This map shows the geographic impact of W Galbraith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W Galbraith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W Galbraith more than expected).

Fields of papers citing papers by W Galbraith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W Galbraith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W Galbraith. The network helps show where W Galbraith may publish in the future.

Co-authorship network of co-authors of W Galbraith

This figure shows the co-authorship network connecting the top 25 collaborators of W Galbraith. A scholar is included among the top collaborators of W Galbraith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W Galbraith. W Galbraith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galbraith, W, et al.. (1994). Antiinflammatory 4,5-Diarylpyrroles: Synthesis and QSAR. Journal of Medicinal Chemistry. 37(7). 988–998. 32 indexed citations
2.
Galbraith, W, et al.. (1993). Topical antiinflammatory dehydroabietylamine derivatives. IV. Bioorganic & Medicinal Chemistry Letters. 3(10). 2087–2092. 19 indexed citations
3.
Lyons-Giordano, Bernadette, Michael A. Pratta, W Galbraith, Gary L. Davis, & Elizabeth C. Arner. (1993). Interleukin-1 Differentially Modulates Chondrocyte Expression of Cyclooxygenase-2 and Phospholipase A2. Experimental Cell Research. 206(1). 58–62. 97 indexed citations
4.
Galbraith, W, et al.. (1991). Antiinflammatory phospholipase-A2 inhibitors. I. European Journal of Medicinal Chemistry. 26(7). 667–676. 18 indexed citations
5.
Batt, Douglas G., et al.. (1990). 2-Substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity. Journal of Medicinal Chemistry. 33(1). 360–370. 61 indexed citations
6.
Neville, Mary E., et al.. (1990). In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1β. Cytokine. 2(6). 456–463. 19 indexed citations
7.
Galbraith, W, et al.. (1990). Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor.. Journal of Pharmacology and Experimental Therapeutics. 254(1). 180–187. 190 indexed citations
8.
Ripka, William C., W. J. Sipio, & W Galbraith. (1989). Molecular modeling in the design of phospholipase A2 inhibitors. Journal of Cellular Biochemistry. 40(3). 279–286. 8 indexed citations
9.
Arner, Elizabeth C., et al.. (1989). Eicosanoid production and cell accumulation induced by intrapleural injection of sodium arachidonate in the rat. Characterization of the model. Biochemical Pharmacology. 38(22). 4151–4154. 2 indexed citations
10.
Harris, Richard R., Douglas G. Batt, W Galbraith, & Neil R. Ackerman. (1989). Topical anti-inflammatory activity of DuP 654, a 2-substituted 1-naphthol. Inflammation Research. 27(3-4). 297–299. 9 indexed citations
11.
Magolda, Ronald L. & W Galbraith. (1989). Design and synthesis of conformationally restricted phospholipids as phospholipase A2 inhibitors. Journal of Cellular Biochemistry. 40(3). 371–386. 15 indexed citations
12.
Lyons-Giordano, Bernadette, et al.. (1989). Interleukin-1β stimulates phospholipase A2 mRNA synthesis in rabbit articular chondrocytes. Biochemical and Biophysical Research Communications. 164(1). 488–495. 74 indexed citations
13.
Galbraith, W, et al.. (1989). Phospholipase A2 (PLA2) activity in undifferentiated U937 cells. Inflammation Research. 27(3-4). 422–424. 8 indexed citations
14.
Arner, Elizabeth C., et al.. (1987). Effect of antiinflammatory drugs on human interleukin-1-induced cartilage degradation. Inflammation Research. 21(3-4). 334–336. 16 indexed citations
15.
Galbraith, W, et al.. (1986). Antiinflammatory consequences of 5-lipoxygenase inhibition.. PubMed. 16. 47–62. 4 indexed citations
16.
Galbraith, W & Irwin Goldstein. (1972). Phytohemagglutinin on the lima bean (Phaseolus lunatus). Isolation, characterization, and interaction with type A blood-group substance. Biochemistry. 11(21). 3976–3984. 90 indexed citations
17.
Galbraith, W & Ido Goldstein. (1970). Phytohemagglutinins: A new class of metalloproteins. Isolation, purification, and some properties of the lectin from Phaseolus lunatus. FEBS Letters. 9(4). 197–201. 71 indexed citations
18.
Galbraith, W & Elizabeth Mayhew. (1965). Rhythm in mitosis and cytoplasmic solid concentration in Landschütz ascites tumour cells. British Journal of Cancer. 19(3). 603–612. 1 indexed citations
19.
Galbraith, W, E. Mayhew, J Sugár, & E. M. F. Roe. (1963). Physical Changes, Measured by Interference Microscopy, in fresh Landschütz Ascites Tumour Cells after Tragacanth and Mannitol Mustard Treatments. British Journal of Cancer. 17(4). 738–744. 4 indexed citations
20.
Galbraith, W, E. Mayhew, & E. M. F. Roe. (1962). Mode of Inhibitory Action of Tragacanth Powder on the Growth of the Landschütz Ascites Tumour. British Journal of Cancer. 16(1). 163–169. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takeki Okumoto Breakdown of academic impact, for papers by Shu Xu Breakdown of academic impact, for papers by Shaukat H. Rangwala Breakdown of academic impact, for papers by Sherrill Nurnberg Breakdown of academic impact, for papers by Daniel Poeckel Breakdown of academic impact, for papers by R. R. Martel Breakdown of academic impact, for papers by Jens Breinholt Breakdown of academic impact, for papers by Tetsuo Ohnuki Breakdown of academic impact, for papers by J L Currie Breakdown of academic impact, for papers by Hyeun‐Wook Chang
Rankless by CCL
2026